Automated WB tumor segmentation: Shiyam Sundar and Beyer examine the transition toward automation in whole-body tumor segmentation using PET/CT imaging, including innovations in artificial intelligence and the need for collaboration across academia, industry, and clinical users.
Page 995
Molecular imaging in gynecology: Sebastiano and colleagues survey recent advances in PET, SPECT, MRI, and fluorescence imaging for diagnosis and management of benign gynecologic conditions, with emphasis on clinical reports, areas of need, and growth opportunities.
Page 998
Aberrant PSMA expression in BLBC: Zhou and colleagues investigate the molecular basis of the application of PMSA-targeting radiopharmaceuticals in breast cancer subtypes, including basallike breast cancer.
Page 1004
PSMA PET/CT in RCC: Sadaghiani and colleagues provide a systematic review and metaanalysis of the utility and detection rate of PSMA PET/CT in staging and evaluation of primary renal cell carcinoma and restaging of metastatic or recurrent disease.
Page 1007
[18F]F-choline PET/CT in PCa: Evangelista and colleagues compare the efficacy of [18F]F-choline PET/CT with that of conventional imaging for staging and managing intermediate- to high-risk prostate cancer.
Page 1013
[18F]AlF-thretide PET/CT in PCa: Zang and colleagues assess the diagnostic accuracy and whole-body radiation dosimetry of [18F]AlF-thretide PET/CT in patients with newly diagnosed, treatment-na?ve prostate cancer, using histopathology as a reference standard.
Page 1021
68Ga-FAPI-46, 18F-FDG PET/CT, and OS: Watanabe and colleagues look at comparative and complementary prognostic values (including for overall survival) of [68Ga]Ga-fibroblast activation protein inhibitor?46 PET/CT and 18F-FDG PET/CT in a range of tumor entities.
Page 1027
PET imaging of NK cells: Pham and colleagues use PET to trace natural killer cell migration to human epidermal growth factor receptor 2?positive HCC1954 breast tumors, focusing on trastuzumab antibody treatment effects on NK cell tumor accumulation.
Page 1035
CEACAM5 imaging in AR− PCa: Imberti and colleagues report on development of an immuno-PET agent targeting the carcinoembryonic antigen– related cell adhesion molecule 5 and evaluate its ability to delineate androgen receptor?negative prostate cancer in preclinical studies.
Page 1043
[111In]-DOTA-h11B6 in mCRPC: Pandit-Taskar and colleagues detail the results of a first-in-human phase 0 trial with 111In-radiolabeled anti?human kallikrein 2 monoclonal antibody to assess hK2 as a target for treatment of metastatic castration-resistant prostate cancer.
Page 1051
Ac-PSMA therapy vs Lu/Ac cocktail: Rathke and colleagues review clinical experience and published data on 225Ac-PSMA-617 treatment in advanced-stage prostate cancer, both as deescalated monotherapy and as part of a 177Lu-PSMA-617/225Ac-PSMA-617 cocktail regimen.
Page 1057
Lesion-based response to PSMA RPT: Yadav and colleagues ask whether baseline lesion-absorbed dose in 177Lu-PSMA-617 radiopharmaceutical therapies can predict corresponding responses and identify connections between lesion-absorbed dose and prostate-specific antigen response.
Page 1064
[177Lu]Lu-DOTATATE response in NETs: Warfvinge and colleagues explore the relationship between tumor-absorbed dose and tumor response in a cohort of patients with neuroendocrine tumors treated with [177Lu]Lu-DOTATATE, with implications for dosimetry-guided regimen design.
Page 1070
PSMA PET/CT before RT: Nikitas and colleagues report on a multicenter randomized phase III trial evaluating the utility of PSMA PET/CT before definitive radiotherapy in men with unfavorable intermediate- or high-risk prostate cancer.
Page 1076
18F-Flotufolastat vs standard imaging: Fleming and colleagues detail findings from the SPOTLIGHT study, assessing the performance of 18F-flotufolastat PET/CT for identifying PSMA-positive lesions in biochemical recurrence of prostate cancer but negative conventional baseline imaging.
Page 1080
Targeted 99mTc and 188Re theranostics: Pham and colleagues report on application of a diphosphine platform incorporating 99mTc into receptor-targeted peptides to label a prostate-PSMA–targeted peptide with 99mTc and 188Re for imaging and radiotherapy of prostate cancer.
Page 1087
Radiosynoviorthesis in synovitis: Desaulniers and colleagues describe the results of a Health Canada?approved trial on the safety and efficacy of intraarticular radionuclide treatment in patients with synovitis refractory to standard treatments.
Page 1095
TB pediatric PET/CT dose reduction: Mingels and colleagues define a lower limit of reduced injected activity in delayed [18F]FDG total-body PET/CT in pediatric oncology patients.
Page 1101
αvβ3 integrin dynamics after AMI: Dietz and colleagues monitor angiogenesis through myocardial integrin αvβ3 expression in patients with ST-segment elevation myocardial infarction and correlate integrin expression levels with subsequent changes in 82Rb PET/CT parameters.
Page 1107
Patient-specific cutoffs in [15O]H2O PET: Hoek and colleagues assess the influences of prior coronary artery disease, sex, and age on optimal cutoffs of hyperemic myocardial blood flow and coronary flow reserve and whether cutoff optimization enhances diagnostic [15O]H2O PET.
Page 1113
Patterns of early Aβ deposition: Lecy and colleagues investigate amyloid-β signals in the perithreshold SUV ratio range using Pittsburgh compound B PET in a population-based study, with implications for diagnosis and understanding of Alzheimer disease phenotypes.
Page 1122
PET/CT and immune-related CNS toxicity: Ma and colleagues analyze 18F-FDG PET/CT images to identify probable biomarkers specific to immune-related central nervous system toxicity in cancer patients treated with immune checkpoint inhibitors.
Page 1129
Granzyme B PET for IBD: Heidari and colleagues use 68Ga-NOTA-GZP PET to target granzyme B, released from cytotoxic T and natural killer cells, and detect early inflammatory bowel disease in murine models of colitis.
Page 1137
Deep learning amyloidosis quantification: Miller and colleagues evaluate a deep learning approach for fully automated volumetric quantitation of 99mTc-pyrophosphate using segmentation of coregistered anatomic structures from CT attenuation maps.
Page 1144
MCT4-based radiomics for [18F]FDG PET: Smeets and colleagues investigate correlations between radiomics features extracted from [18F]FDG PET images and histologic expression patterns of monocarboxylate transporter-4, a glycolytic marker in pancreatic cancer.
Page 1151
AI-based prediction of brain tumor foci: Lohmann and colleagues present a case study in suspected glioma illustrating the potential of artificial intelligence?based decision support for diagnostic and treatment planning based on amino acid PET.
Page 1160
[68Ga]Ga-FAPI-46 uptake and infection: Cuzzani and colleagues describe a case of actinomycosis in which [68Ga]Ga-FAPI-46 PET findings mimic lung cancer.
Page 1161
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.